A Study in Adult Subjects With Chronic Hepatitis B Infection to Support the Development of Immunological Assays
研究概览
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
-
Brussels、比利时、1070
- GSK Investigational Site
-
Bruxelles、比利时、1000
- GSK Investigational Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Written informed consent obtained from the subject.
- Subjects who the investigator believes that they can and will comply with the requirements of the protocol.
- A male or female between, and including, 18 and 65 years of age at study start.
- Evidence of chronic hepatitis B infection as per medical record.
- Female subjects of non-childbearing potential may be enrolled in the study.
- Female subjects of childbearing potential may be enrolled in the study, if the subject has practiced adequate contraception for 30 day prior to study start.
In addition to these general inclusion criteria, subjects should satisfy ALL specific criteria according to the specified group maximum 6 months prior to Visit 1 as per medical records:
Group A: Immune tolerant patients
- Viral load: > 2x107 IU/mL of HBV DNA
- HBeAg positive
- Normal levels of ALT according to lab range Group B: HBeAg positive chronic hepatitis B patients
- Viral load: > 2x104 IU/mL of HBV DNA
- HBeAg positive
- Increased levels of ALT and/or evidence of chronic hepatitis on liver biopsy Group C: Healthy carriers
- Viral load: not exceeding 2x103 IU/mL of HBV DNA
- HBeAg negative
- Normal levels of ALT measured at least twice, at least 3 months apart, during the last 6 months Group D: HBeAg negative chronic hepatitis B patients
- Viral load: > 2x103 IU/mL of HBV DNA
- HBeAg negative
- Increased levels of ALT and/or evidence of chronic hepatitis on liver biopsy
Exclusion Criteria:
- Any hepatitis B specific treatment prior to blood sampling at Visit 1.
- Any known clinically significant anaemia or any other condition within 7 days prior to study entry (Visit 1) as per medical records that would preclude the drawing of blood as described in the protocol.
- Receipt of live attenuated vaccines within 30 days preceding the blood sampling at Visit 1 and the administration of a pandemic influenza vaccine within 21 days preceding the blood sampling at Visit 1.
- Receipt of blood products within 120 days prior to study entry (Visit 1).
- Receipt of immunoglobulins within 120 days prior to study entry (Visit 1).
- Receipt of interferon within 120 days prior to study entry (Visit 1).
- Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding study start, or planned use during the study period.
- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
- History of immunosuppressive or immune-mediated disorders including autoimmune diseases, human immunodeficiency virus (HIV) infection and hepatitis C infection, based on medical history and physical examination (no laboratory testing required).
- Pregnant or lactating female.
- History of malignancy (unless there has been surgical excision followed by a sufficient observation period, of at least 5 years, to give a reasonable assurance of sustained cure and which, in the estimate of the investigator, is not likely to recur during the study period).
- Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs (including chloroquine) within six months prior to the blood sampling at Visit 1 (for corticosteroids, this will mean prednisone ≥10 milligram/day (10 mg/day), or equivalent). Inhaled and topical steroids are allowed.
- History of type I or type II diabetes mellitus including cases controlled with diet alone (a subject with past gestational diabetes is eligible).
- History of major congenital defect.
- Subjects with a history of, or current, alcohol or substance abuse.
学习计划
研究是如何设计的?
设计细节
- 主要用途:其他
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
其他:Immune tolerant patients Group
Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B viruss (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.
|
A single blood sample was to be taken from all subjects at the study visit.
No study-related treatment was given to the study participants.
|
|
其他:HBeAg positive Group
HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with activee inflammation and varying degrees of liver fibbrosis.
|
A single blood sample was to be taken from all subjects at the study visit.
No study-related treatment was given to the study participants.
|
|
其他:Inactive carriers Group
Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.
|
A single blood sample was to be taken from all subjects at the study visit.
No study-related treatment was given to the study participants.
|
|
其他:HBeAg negative Group
HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.
|
A single blood sample was to be taken from all subjects at the study visit.
No study-related treatment was given to the study participants.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1
大体时间:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, ICOS, HLA-DR, PD-1 and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
|
Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1
大体时间:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, ICOS, HLA-DR, PD-1 and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
|
Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67
大体时间:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, GITR, anti-Foxp3 and Ki67.
|
At the time of the visit for each subject (i.e., Day 0)
|
|
Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67
大体时间:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, GITR, anti-Foxp3 and Ki67.
|
At the time of the visit for each subject (i.e., Day 0)
|
|
Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L
大体时间:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, CCR7, CD62L and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
|
Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L
大体时间:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, CCR7, CD62L and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
|
Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2)
大体时间:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, CD39, TNFR2 and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
|
Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2
大体时间:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, CD39, TNFR2 and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
|
Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40
大体时间:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, CTLA4, OX40 and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
|
Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40
大体时间:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, CTLA4, OX40 and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
|
Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples
大体时间:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD69, LAP and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
|
Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples
大体时间:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD69, LAP and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
|
Frequency of HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Frozen Samples
大体时间:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD69, LAP and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples
大体时间:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD40-L, IFNg, IL-2 and IL-17. Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001). |
At the time of the visit for each subject (i.e., Day 0)
|
|
Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples
大体时间:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD8, CD40-L, IFNg, IL-2 and IL-17. Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001). |
At the time of the visit for each subject (i.e., Day 0)
|
|
Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples
大体时间:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD40-L, IFNg, IL-2 and IL-17. Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001). |
At the time of the visit for each subject (i.e., Day 0)
|
|
Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples
大体时间:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD8, CD40L, IFNg, IL-2 and IL-17. Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001). |
At the time of the visit for each subject (i.e., Day 0)
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.